<DOC>
	<DOCNO>NCT02273609</DOCNO>
	<brief_summary>The primary objective study determine rate INR control patient nonvalvular AF daily attend primary care Spain . PAULA observational retrospective/cross-sectional multicenter study . Patients age ≥18 year old , nonvalvular AF , treat VKAs least one year primary care include study . To include , least 80 % INR value past 12 month available . Before inclusion , patient provide write consent . Clinical data ( biodemographic data , comorbidities , treatment , thromboembolic/bleeding risk ) record clinical history patient moment inclusion . INR value take previous 12 month inclusion . Poor INR control consider percent time therapeutic INR range ( TTR ) &lt; 65 % ( calculated Rosendaal method ) &lt; 60 % direct method ( proportion INR value ) . A total 1,524 patient include study .</brief_summary>
	<brief_title>INR Control Atrial Fibrillation Primary Care Spain ( PAULA )</brief_title>
	<detailed_description>Vitamin K antagonist ( VKAs ) traditionally use long-term prevention thromboembolic complication patient atrial fibrillation ( AF ) . Because variability dose response VKAs narrow therapeutic window , monitor degree anticoagulation mandatory . The international normalized ratio ( INR ) provide standardized measure VKA anticoagulant effect . The INR keep within narrow range ( therapeutic INR target 2.0-3.0 ) control intensity anticoagulation . The primary objective study determine rate INR control patient nonvalvular AF daily attend primary care Spain . PAULA observational retrospective/cross-sectional multicenter study support three main Spanish primary care scientific society : Sociedad Española de Médicos de Atención Primaria ( SEMERGEN ) , Sociedad Española de Medicina de Familia Comunitaria ( SEMFYC ) Sociedad Española de Médicos Generales de Familia ( SEMG ) . Patients age ≥18 year old , nonvalvular AF , treat VKAs least one year primary care include study . To include , least 80 % INR value past 12 month available . Before inclusion , patient provide write consent . Clinical data ( biodemographic data , comorbidities , treatment , thromboembolic/bleeding risk ) record clinical history patient moment inclusion . INR value take previous 12 month inclusion . Poor INR control consider percent time therapeutic INR range ( TTR ) &lt; 65 % ( calculated Rosendaal method ) &lt; 60 % direct method ( proportion INR value ) . The study approve ethic committee hospital La Paz , Madrid . A total 1,524 patient include study .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Patients age ≥18 year old nonvalvular AF , treat VKAs least one year primary care At least 80 % INR value past 12 month available . Written consent provide inclusion . Patients sign understand write consent . Participating clinical trial last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Vitamin K antagonist</keyword>
	<keyword>INR control</keyword>
</DOC>